Loading organizations...
§ Private Profile · One Kendall Square 1400W, Suite#14201. Cambridge MA 02139. UNITED STATES OF AMERICA
Triplet Therapeutics is a technology company.
Triplet Therapeutics focuses on developing novel therapeutic approaches for repeat expansion disorders, including Huntington's disease, myotonic dystrophy, and spinocerebellar ataxia. The company's core product strategy involves targeting these debilitating conditions at their genetic source. By leveraging insights from human genetics, Triplet aims to identify and develop drugs that directly address the expanded DNA sequences responsible for these diseases, representing a distinct mechanism of action in the field.
Founded in 2019, Triplet Therapeutics was established with the understanding that a fundamental shift was needed in treating complex genetic disorders. The company's inception was driven by the opportunity to intervene upstream in disease pathology, rather than merely managing symptoms. This founding insight underscores a commitment to precision medicine, aiming to correct the underlying genetic defects that cause a spectrum of severe neurological and neuromuscular conditions.
Triplet Therapeutics primarily serves patient populations afflicted by inherited repeat expansion disorders. The company's long-term vision centers on delivering transformative therapies that go beyond current standards of care. By addressing the root genetic cause of these conditions, Triplet seeks to provide impactful treatments that significantly alter disease progression and improve the lives of individuals with these challenging and currently underserved medical needs.
Triplet Therapeutics has raised $49.0M across 1 funding round.
Triplet Therapeutics has raised $49.0M in total across 1 funding round.
Triplet Therapeutics has raised $49.0M across 1 funding round. Most recently, it raised $49.0M Series A in December 2019.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 1, 2019 | $49M Series A | Shinichiro Fuse | Atlas Venture, OrbiMed, Alexandria Venture Investments, Invus, Partners Innovation Fund | Announced |
Triplet Therapeutics was a biotechnology company founded in 2018 or 2019 that developed antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) to treat repeat expansion disorders (REDs), a group of over 40 genetic diseases including Huntington’s disease, myotonic dystrophy, and spinocerebellar ataxias.[1][3][4] It targeted the DNA damage response (DDR) pathway, the common underlying driver of these disorders, serving patients with unmet needs in neurodegenerative and neuromuscular conditions by aiming to halt disease onset and progression upstream of existing approaches.[1][2][3] The company raised $59 million (some reports note over $80 million including debt) from investors like Atlas Venture and MPM Capital but ceased operations in October 2022 due to financial struggles and clinical toxicity issues with its lead compound, leading to an asset sale via assignment for the benefit of creditors (ABC).[1][2][5]
Triplet Therapeutics emerged from insights into human genetics linking the DDR pathway to REDs, founded by Nessan Bermingham, Ph.D. (CEO, serial biotech entrepreneur and Atlas Venture venture partner), Atlas Venture, and Andrew Fraley, Ph.D..[3] Bermingham, with prior experience in biotech ventures, assembled the team to pioneer a new treatment paradigm, launching with a $59 million financing round announced by Pfizer in late 2020 amid a biotech funding boom fueled by Covid-19.[1][3] Early traction included filing 7 patents on topics like DNA, gene expression, and abnormal psychology, and initiating the Shield-HD study for Huntington’s, which continued under CHDI after shutdown.[1][2] However, promising preclinical results gave way to central nervous system toxicity in trials, short runway, and investor fatigue, culminating in quiet closure announced by Bermingham on LinkedIn.[2][5]
Triplet rode the genetic medicines wave in biotech, targeting REDs amid surging interest in RNA therapeutics (ASOs/siRNAs) post-Alnylam successes and the 2020 funding surge.[1][3] Timing aligned with DDR pathway validation in neurodegeneration, but market forces like clinical toxicity risks, investor pullback post-Covid boom, and short runways exposed startup vulnerabilities in capital-intensive biotech.[2][5] Its assets' acquisition via ABC preserved value for creditors (including venture lenders), influencing the ecosystem by enabling tech transfer—e.g., Shield-HD data to CHDI—while underscoring tools like ABCs as faster alternatives to bankruptcy for distressed biotechs.[5] This reflects broader pressures on early-stage platforms without near-term clinical wins.
Triplet's story exemplifies biotech's high-stakes gamble: bold DDR targeting promised paradigm shifts for REDs, but toxicity and funding droughts led to asset liquidation rather than breakthroughs.[2][5] Its IP and data live on through undisclosed buyers, potentially fueling rivals in genetic therapies amid advancing CRISPR and RNA platforms. Looking ahead, trends like AI-driven target validation and derisked pipelines will shape survivors, but Triplet warns of execution pitfalls in a maturing, cash-conscious biotech landscape—reminding investors that even well-funded platforms need clinical momentum to endure.[1][2]
Triplet Therapeutics has raised $49.0M in total across 1 funding round.
Triplet Therapeutics's investors include Shinichiro Fuse, Atlas Venture, OrbiMed, Alexandria Venture Investments, Invus, Partners Innovation Fund.